Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 2, 2008, Pages 125-132

  Grainger, Elizabeth M ^a   Kim, H Sunny ^a   Monk, J Paul ^a   Lemeshow, Stanley A ^a   Gong, Michael ^a   Bahnson, Robert R ^a   Clinton, Steven K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adult behavior; Cancer; Complementary therapy; Dietary supplements

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; CALCIUM; FOLIC ACID; HERBACEOUS AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; SELENIUM;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DIET SUPPLEMENTATION; HUMAN; MALE; NUTRIENT; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; DIETARY SUPPLEMENTS; DRUGS, NON-PRESCRIPTION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 39649093886     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.01.016     Document Type: Article

References (34)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo 8 (1994) 439-443
3. Thompson I.M., Tangen C.M., and Goodman P. The Prostate Cancer Prevention Trial: Design, status, and promise. World J Urol 21 (2003) 28-30
4. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
5. Clark L.C., Combs G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276 (1996) 1957-1963
6. Corcoran N.M., Najdovska M., and Costello A.J. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171 (2004) 907-910
7. Heinonen O.P., and Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
8. John E.M., Dreon D.M., Koo J., et al. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol 89-90 (2004) 549-552
9. Zhong W., and Oberley T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61 (2001) 7071-7078
10. McCullough M.L., and Giovannucci E.L. Diet and cancer prevention. Oncogene 23 (2004) 6349-6364
11. Basler J.W., and Piazza G.A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171 (2004) S59-S62
12. Platz E.A., Fleitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2007) 1819-1825
13. Sandler R.S., Halabi S., Kaplan E.B., et al. Use of vitamins, minerals and nutritional supplements by participants in a chemoprevention trial. Cancer 91 (2001) 1040-1045
14. Fitzpatrick A.L., Daling J.R., Furberg C.D., et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11 (2001) 534-542
15. de la Taille A., Buttyan R., Hayek O., et al. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164 (2000) 1229-1234
16. Gerber G.S., Kuznetsov D., Johnson B.C., et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 58 (2001) 960-964
17. Pytel Y.A., Vinarov A., Lopatkin N., et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 19 (2002) 297-306
18. Small E.J., Frohlich M.W., Bok R., et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18 (2000) 3595-3603
19. Bernstein B.J., and Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology 15 (2001) 1272-1278
20. Kao G.D., and Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88 (2000) 615-619
21. Radimer K., Bindewald B., Hughes J., et al. Dietary supplement use by US adults: Data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160 (2004) 339-349
22. Hoggatt K.J., Bernstein L., Reynolds P., et al. Correlates of vitamin supplement use in the United States: Data from the California Teachers Study cohort. Cancer Causes Control 13 (2002) 735-740
23. Dwyer J., Picciano M.F., and Raiten D.J. Collection of food and dietary supplement intake data: What We Eat in America- NHANES. J Nutr 133 (2003) 590S-600S
24. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey. JAMA 287 (2002) 337-344
25. Neuhouser M.L., Kristal A.R., Patterson R.E., et al. Dietary supplement use in the prostate cancer prevention trial: Implications for prevention trials. Nutr Cancer 39 (2001) 12-18
26. White E., Patterson R.E., Kristal A.R., et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159 (2004) 83-93
27. Messina M., Gardner C., and Barnes S. Gaining insight into the health effects of soy but a long way still to go: Commentary on the fourth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. J Nutr 132 (2002) 547S-551S
28. Zhou J.R., Gugger E.T., Tanaka T., et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129 (1999) 1628-1635
29. Zhou J.R., Mukherjee P., Gugger E.T., et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58 (1998) 5231-5238
30. Erdman Jr. J.W. AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 102 (2000) 2555-2559
31. Lampe J.W., Gustafson D.R., Hutchins A.M., et al. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 8 (1999) 699-707
32. Boileau T.W., Liao Z., Kim S., et al. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 95 (2003) 1578-1586
33. Clinton S.K. Tomatoes or lycopene: A role in prostate carcinogenesis?. J Nutr 135 (2005) 2057S-2059S
34. Giovannucci E., Ascherio A., Rimm E.B., et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87 (1995) 1767-1776